Annexon Biosciences

We had a great time presenting at the 2024 Peripheral Nerve Society Meeting. Thank you to everyone who stopped by our booth and attended our poster presentations, plenary session and symposium as well as our colleagues and partners, Dr. David Cornblath, Dr. Bart Jacobs, Dr. Jeff Allen and Lisa Butler, for their hard work and collaboration. #PNS24

Listen to Lisa Butler of GBS|CIDP Foundation International and Dr. Karissa Gable, Associate Professor of Neurology at Duke University, discuss how early diagnosis and treatment of #GuillainBarreSyndrome (GBS) can help maximize health later on. There is a limited treatment window in GBS where the extent of acute nerve damage determines the level of functional outcomes in the long run. 

Today at the 2024 Peripheral Nerve Society Meeting, we presented new data analyses from our pivotal Phase 3 study in #GuillainBarrésyndrome (GBS), evaluating our investigational C1q-Targeted Immunotherapy as a potential treatment option for this devastating neurological emergency. We also presented flash oral and poster presentations of sub-analyses from our Phase 1b study and methodology for our ongoing real-world evidence study, respectively. Read more about the presentations here: bit.ly/3REuNDh #PNS24

Over 22,000 patients are hospitalized in U.S. and Europe each year with Guillain Barré Syndrome (#GBS). Following infection, complement‐activating autoantibodies attack nerves leading to nerve damage & acute paralysis. GBS can happen to anyone, anytime and anywhere. We’re developing an investigational therapy with the goal of helping patients with GBS get better sooner. Learn more about our research and recent positive Phase 3 results: https://rb.gy/gq4bu0

We are excited to share that we will be presenting new data from our pivotal Phase 3 trial for the treatment of #GuillainBarrésyndrome (GBS), as well as a comparative analysis against current standard of care and research into biomarkers at the 2024 Peripheral Nerve Society Meeting. We will also be hosting a symposium and will have a booth – hope to see you there! https://shorturl.at/RUjTy #PNS24

Guillain Barré Syndrome (GBS) is a neurological emergency requiring urgent intervention, with a limited time window to achieve a therapeutic effect. GBS can affect anyone at anytime and anywhere. We stand with the #GuillainBarréSyndrome community in committing to improve GBS treatment for patients worldwide. Hear directly from GBS patients about their experience with this devastating disease below.

Today we are excited to announce positive topline data from our randomized placebo-controlled pivotal Phase 3 trial in patients with #GuillainBarrésyndrome (#GBS).    Thank you to the patients and investigators who participated in this trial. We are thrilled with these results and couldn’t have done it without your support.   Detailed results here: https://rb.gy/n1netu Join our webcast presentation at 8:30 am ET today. 

We look forward to presenting topline results from our pivotal Phase 3 clinical trial in #GuillainBarrésyndrome (#GBS) tomorrow, Tuesday, June 4. Join us on the webcast at 8:30 a.m. ET https://rb.gy/c68i4g

Today we announced our first quarter 2024 financial results and key anticipated milestones. Read more here: https://rb.gy/gvcu53

Today, our Associate Director of Research Alessia Tassoni and David Boyer, MD of Retina-Vitreous Associates Medical Group, presented new neuroprotection data in geographic atrophy (GA) at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The Phase 2 ARCHER results demonstrated the rapid potential of our investigational therapy to protect vision and vision-associated structures in patients with GA. Our preclinical data further demonstrates the role of C1q and the importance of photoreceptor synapse protection. Additional details on data here: https://rb.gy/4p9jk1 #ARVO24 #GeographicAtrophy